Pershing Square
new idea generation remains robust | Pershing Square
Company
Deck Type
Sector
Industry
Deck date
February 2020
Slide
22 of 62
Related slides by other companies
AbCellera
Results
May 2023
capital allocation to maximize long term value while minimizing risk forward integration to expand the capabilities of our engine including manufacturing regulatory and clinical activities develop technology to unlock new target classes and modalities including cell and and ion channels build the portfolio by advancing high quality programs and partnerships we | AbCellera
AstraZeneca
Results
November 2023
capital allocation capital allocation strategy unchanged investments to drive future growth reinvestment in the business free post currently projects in phase development investments behind launches in new indications and strengthening leadership in existing therapy areas continued investments in new technologies and platforms including cell and gene therapies progressive dividend policy value accretive deals continue to leverage partnerships to drive innovation and bring medicines to markets priority remains in our business new approvals in major markets | AstraZeneca
Diploma
Results
May 2023
building high quality scalable businesses for sustainable organic growth grow scale deliver value responsibly | Diploma
OpenText
Investor Presentation
January 2020
acquire business system creates strategic value | OpenText
Other recent decks by Pershing Square
See all presentations (16 decks)
Investor Presentation
February 2025
Investor Presentation
February 2024
Investor Presentation
February 2023
Activist
February 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights